Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA

OBJECTIVES: Etanercept biosimilars show comparable efficacy to their originators among biologic-naïve patients with RA in randomized controlled trials. Nationwide guidelines have obligated prescribing of etanercept biosimilars from 2016, resulting in significant cost savings. This analysis aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kearsley-Fleet, Lianne, Rokad, Aasiyah, Tsoi, Man-Fung, Zhao, Sizheng Steven, Lunt, Mark, Watson, Kath D, Hyrich, Kimme L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691930/
https://www.ncbi.nlm.nih.gov/pubmed/36943379
http://dx.doi.org/10.1093/rheumatology/kead127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691930/
https://www.ncbi.nlm.nih.gov/pubmed/36943379
http://dx.doi.org/10.1093/rheumatology/kead127

Ejemplares similares